ERCC6L2 and Bone marrow hypocellularity: <h4>Abstract</h4>The hallmark of ERCC6L2 disease (ED) is a highly penetrant progression from bone marrow failure to erythroid-predominant, TP53-mutated myeloid malignancy with a dismal prognosis.